Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.
about
In vivo involvement of polymorphonuclear neutrophils in Leishmania infantum infectionActivation of invariant NKT cells exacerbates experimental visceral leishmaniasisCD4+ Recent Thymic Emigrants Are Recruited into Granulomas during Leishmania donovani Infection but Have Limited Capacity for Cytokine ProductionRegulation of immunity during visceral Leishmania infectionA curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapyInhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice.Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infectionVCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis.Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasisComparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins.Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection.Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.Evaluation of TNF-α, IL-4, and IL-10 and parasite density in spleen and liver of L. (L.) chagasi naturally infected dogs.Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasisClinical and experimental advances in treatment of visceral leishmaniasis.Early gene expression of NK cell-activating chemokines in mice resistant to Leishmania major.Enhanced hematopoietic activity accompanies parasite expansion in the spleen and bone marrow of mice infected with Leishmania donovaniInterleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.Tissue granuloma structure-function in experimental visceral leishmaniasis.Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasisBalancing immunity and pathology in visceral leishmaniasis.Leishmania donovani infection induces anemia in hamsters by differentially altering erythropoiesis in bone marrow and spleenResponses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection.Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathologyDistinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.The Schistosoma mansoni hepatic egg granuloma provides a favorable microenvironment for sustained growth of Leishmania donovani.IRF-5-Mediated Inflammation Limits CD8+ T Cell Expansion by Inducing HIF-1α and Impairing Dendritic Cell Functions during Leishmania InfectionA role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection.IL-23 in infections, inflammation, autoimmunity and cancer: possible role in HIV-1 and AIDSEvaluation of leishmanicidal activity and cytotoxicity of Ricinus communis and Azadirachta indica extracts from western Kenya: in vitro and in vivo assays.T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvantNK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs.Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycanNeutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani.
P2860
Q24805383-79BC9905-DDC9-4DB3-B811-B31A1212C3FDQ27318814-08C3C225-4FEB-4BFD-98F9-FEB07918ED12Q27321353-940C3355-1434-4BBA-BEF8-41C97083A93BQ28066034-F883280C-2125-4C21-B2AB-50B3DA89075FQ28474921-4BF8E0E2-A2F4-46D7-9E81-17DEC86B9FFFQ30493887-39DFFF20-30DD-4F43-858F-FA241D7A386BQ31036509-2F35BA3A-A8F6-4CC7-A5D0-9669FE30D914Q33370533-7C6D2BA9-D1F9-44CF-B25C-B3C3902CE4A0Q33463435-44D582C6-0B6F-4D9A-B428-720E2C33CD75Q33615236-277BC290-CDE5-4F26-9926-A319D1AD8A5BQ33732102-AC85AA71-F722-4BD9-82A4-921AFB913B51Q33799144-46F51425-E6F7-4277-B3C4-943C8E096E6BQ33818084-5167FF4C-BFAD-4B06-8337-779F203520A2Q33873567-31ABB125-BFE9-43CF-B90B-16712CC4489EQ33883498-53EFBF19-763B-4DAA-86DB-E59B7B53DD6FQ33979661-19F6216A-95BA-4E50-82B1-4A48DADC38E0Q33982648-4BAFA557-3679-418C-B5A3-FF2C9BE4A16CQ34001286-C4EDC01E-F266-42FA-A2E4-968D1F891132Q34003789-754FC571-C9E2-4785-B399-E88B1CFA1BF1Q34181985-746BFBDF-AD84-4450-99F9-6D16BC2AA661Q34434760-CD47C9DF-5A03-4A6F-8B2A-01E04E8F7287Q34521577-BA31DBAD-16EB-4DF0-882B-8C5A674D0B93Q34587432-BCE259A1-40A4-42FC-8780-C870527D890DQ34637852-8673AACA-104E-403C-83D5-D827045FF7AAQ34721430-12230FA1-78D5-4722-A2B3-C698292C3D0CQ34955529-A590963E-0055-45C9-B9E5-5A5CF35C284DQ35070810-5AB12AA1-7B8C-4751-813A-2AF142E8A629Q35103595-1D775863-720C-4174-B01E-4D3E5049459BQ35165825-E4838B13-DA6C-4104-B17A-DDADCABC0CDDQ35222060-996EB673-518A-4E25-B681-1C8C312A8466Q35653927-6CEECBFC-7A29-42A6-B106-C1B4B802D9FBQ35747613-AD1EA967-F4CB-4FB1-90F3-D7BFEAC43F6FQ35784621-CC0BF29E-AFDC-4EC2-BF19-B0B7E3CFF25CQ35833805-ED9ADC54-29C4-4D0A-9257-C2FC9F71E3BFQ35928348-4F9FA5A7-B9C5-4706-AC05-EA354155B73FQ36141819-578D79C6-DBEC-497B-A4F9-D5293D169CFFQ36229299-21DEAECF-95F0-4623-BB60-3DB9C6119BD7Q36376714-DB290965-0BB6-4B2F-BEA9-B91EC402C52AQ36403849-AFC9D947-2482-4BE0-B055-DCBF567E4667Q36421468-F9DC8119-B69B-4636-A996-22F5527CC282
P2860
Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Neutralization of IL-12 demons ...... ontrol of Leishmania donovani.
@en
type
label
Neutralization of IL-12 demons ...... ontrol of Leishmania donovani.
@en
prefLabel
Neutralization of IL-12 demons ...... ontrol of Leishmania donovani.
@en
P2093
P2860
P1476
Neutralization of IL-12 demons ...... control of Leishmania donovani
@en
P2093
M L Murphy
S E Cotterell
P2860
P304
P356
10.1002/(SICI)1521-4141(199802)28:02<669::AID-IMMU669>3.0.CO;2-N
P407
P577
1998-02-01T00:00:00Z